Skip to content
777 Sourcing.

Capability

pre-clinical and clinical neuropsychiatric drug development

Suppliers
1
States & provinces
1
Countries
1

1 pre-clinical and clinical neuropsychiatric drug development supplier across 1 states and provinces in 1 country. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.

Suppliers

DIAMOND THERAPEUTICS USA INC.

BIRMINGHAM, AL

Diamond Therapeutics is a psychedelic pharmaceutical company developing safe, FDA, EMA and Health Canada approved therapies for neuropsychiatric conditions, starting with sub-perceptual psilocybin-based medicines. Its first clinical program focuses on accessible psilocybin-based drugs intended to deliver rapid therapeutic outcomes without perceptual side effects. It is also advancing a pipeline of tryptamine analogs and small organic molecules that modulate selective serotonin receptors and neurotrophic receptor signalling.

clinical trialsdrug discoveryformulation development

Compiled from public sources

Related capabilities

Other processes offered by the shops that list pre-clinical and clinical neuropsychiatric drug development.

Browse all capabilities